⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen USA - Deutsch USA - English
prnewswire.com
ABBV
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
prnewswire.com
AGN
NOVN
EXEL
ABBV
BMY
EISAY
TKPY
MRK
AbbVie presentará datos de fase 3 de ECLIPSE en el 19º Congreso Europeo de Cefaleas USA - español USA - English
prnewswire.com
ABBV
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
prnewswire.com
ABBV
GILD
BMY
REGN
XBI
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
prnewswire.com
ABBV
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
globenewswire.com
ABBV
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035
globenewswire.com
BIIB
GILD
BMY
ABBV
MRNA
CRSP
NTLA
EDIT
Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
prnewswire.com
JNJ
ABBV
VRTX
AZN
INCY
BIIB
NVS
ROG
PFE
BMY
8MM Respiratory Syncytial Virus Prophylaxis Drug Forecast Report 2025: A $7.2 Billion Market by 2030, Prophylactic Options to Continue to Diversify Due to Strength of Late-stage Pipeline
globenewswire.com
AZN
ABBV
SNY
MRK
GSK
PFE
MRNA
Hepatic Encephalopathy Market Analysis and Forecast, 2025-2035 - Key Players Shape the Market with Strategic Partnerships and Innovative Therapies
globenewswire.com
LNN
ABBV